<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ALBUMINAR-20- albumin human solution </strong><br>CSL Behring LLC<br></p></div>
<h1>Albumin (Human) USP, 20% <br>Albuminar<span class="Sup">®</span>-20</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DL"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">R<span class="Sub">x</span> only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="DESCRIPTION"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Albumin (Human) 20%, Albuminar<span class="Sup">®</span>-20 is a sterile aqueous solution of albumin obtained from large pools of adult human venous plasma by low temperature controlled fractionation according to the Cohn process. It is stabilized with 0.016 M sodium acetyltryptophanate and 0.016 M sodium caprylate and heated at 60°C for 10 hours.</p>
<p>All Source Plasma used in the manufacture of this product was tested by FDA-licensed Nucleic Acid Testing (NAT) for HBV, HCV, and HIV-1 and found to be nonreactive (negative).</p>
<p>Albuminar<span class="Sup">®</span>-20 is a solution containing in each 100 mL 20 grams of human albumin, osmotically equivalent to 400 mL of normal human plasma. The pH of the solution is adjusted with sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, sodium hydroxide, or acetic acid. Approximate concentrations of significant electrolytes per liter are:  sodium 130-160 mEq; and potassium-n.m.t. 1 mEq. The solution contains no preservative. This product has been prepared in accordance with the requirements established by the Food and Drug Administration and is in compliance with the standards of the United States Pharmacopeia. Albuminar<span class="Sup">®</span>-20 is to be administered by the intravenous route.</p>
<p>The heat treatment step employed in the manufacture of Albuminar<span class="Sup">®</span>-20, pasteurization of the final container at 60°C for 10 hours, has been validated in a series of <span class="Italics">in vitro</span> experiments for its capacity to inactivate Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus type 1 (HIV-1), and the following model viruses: Bovine Viral <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> Virus (BVDV - an enveloped virus used as a model for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus), Pseudorabies (PrV - a large, enveloped virus), and Encephalomyocarditis Virus (EMC - a small non-enveloped virus). For each virus studied, three independent experiments were conducted using Albumin (Human) 5%, Albuminar<span class="Sup">®</span>-5 and Albumin (Human) 25%, Albuminar<span class="Sup">®</span>-25 with the following results.<span class="Sup"> 1</span></p>
<table width="70%">
<caption><span>Pasteurization (60°C for 10 hours) Viral Reduction Studies (log<span class="Sub">10</span> reduction)</span></caption>
<col align="left" valign="middle" width="25%">
<col align="center" valign="middle" width="75%">
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Virus</td>
<td class="Rrule" align="center">Albumin (Human) 5%, Albuminar<span class="Sup">®</span>-5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">HIV-1</td>
<td class="Rrule" align="center">&gt;5.44, &gt;6.38 and &gt;6.31</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">BVDV</td>
<td class="Rrule" align="center">&gt;6.01, &gt;6.76 and &gt;6.55</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">PrV</td>
<td class="Rrule" align="center">&gt;7.30, &gt;7.68 and &gt;7.63</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left">EMC</td>
<td class="Rrule Toprule" align="center">&gt;7.38, &gt;7.97 and &gt;7.97</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Virus</td>
<td class="Rrule" align="center">Albumin (Human) 25%, Albuminar<span class="Sup">®</span>-25</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">HIV-1</td>
<td class="Rrule" align="center">&gt;5.50, &gt;6.57 and &gt;6.64</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">BVDV</td>
<td class="Rrule" align="center">&gt;5.99, &gt;5.81 and &gt;5.32</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">PrV</td>
<td class="Rrule" align="center">&gt;7.32, &gt;7.20 and &gt;7.42</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">EMC</td>
<td class="Rrule" align="center">&gt;7.10, &gt;7.89 and &gt;7.87</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Albuminar<span class="Sup">®</span>-20 is active osmotically and is therefore important in regulating the volume of circulating blood. When injected intravenously, 50 mL of 20% albumin draws approximately 140 mL of additional fluid into the circulation within 15 minutes, except in the presence of marked <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. This extra fluid reduces hemoconcentration and blood viscosity. The degree of volume expansion is dependent on the initial blood volume. When the circulating blood volume has been depleted, the hemodilution following albumin administration persists for many hours. In individuals with normal blood volume, it usually lasts only a few hours.</p>
<p>Albumin (Human), unlike whole blood or plasma, is considered free of the danger of <span class="product-label-link" type="condition" conceptid="4291005" conceptname="Viral hepatitis">viral hepatitis</span> because it is heated at 60°C for 10 hours. Albuminar<span class="Sup">®</span>-20 may be given in conjunction with other parenteral fluids such as saline, dextrose or sodium lactate. It is convenient to use since no cross-matching is required and the absence of cellular elements removes the danger of sensitization with repeated infusions.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">SHOCK</span></h2>
<p class="First">Albuminar<span class="Sup">®</span>-20 is indicated in the emergency treatment of <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> due to <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, operations and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, in the treatment of injuries of such severity that <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, although not immediately present, is likely to ensue and in other similar conditions where the restoration of blood volume is urgent. If there has been considerable loss of red blood cells, transfusion with packed red blood cells is indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">BURNS</span></h2>
<p class="First">Albuminar<span class="Sup">®</span>-20 is indicated in conjunction with adequate infusions of crystalloid to counteract hemoconcentration and the loss of protein, electrolytes and water that usually follow severe <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>. Because of changes in permeability, little administered albumin is likely to be retained intravascularly in the first 12 hours after a major burn. However, an optimum regimen for the use of colloid, electrolytes and water in the treatment of <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span> has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">HYPOPROTEINEMIA</span></h2>
<p class="First">Albuminar<span class="Sup">®</span>-20 may be used in acutely hypoproteinemic patients in the presence or absence of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Albuminar<span class="Sup">®</span>-20 is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> and in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to human albumin.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Infusion of protein-containing solutions such as Albuminar<span class="Sup">®</span>-20 that have been excessively or inappropriately diluted with hypotonic solutions such as sterile water for injection may result in severe <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. Please refer to the <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span> section for information about the recommended diluents for Albuminar<span class="Sup">®</span>-20, which are normal saline and 5% dextrose.</p>
<p>Do not use if the solution is turbid. Since this product contains no antimicrobial preservative, do not begin administration more than 4 hours after the container has been entered.</p>
<p>Albuminar<span class="Sup">®</span>-20 is made from human plasma. Products made from human plasma may contain infectious agents such as viruses, that can cause disease. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and by inactivating and/or removing certain viruses during manufacture. The manufacturing procedure for Albuminar<span class="Sup">®</span>-20 includes processing steps designed to reduce further the risk of viral transmission. Stringent procedures utilized at plasma collection centers, plasma testing laboratories, and fractionation facilities are designed to reduce the risk of viral transmission. Albuminar<span class="Sup">®</span>-20 is pasteurized in the final container at 60.0 +/- 0.5°C for 10-11 hours. Virus elimination/inactivation is also achieved by the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> alcohol fractionation process. (See <span class="Bold"><a href="#DESCRIPTION">DESCRIPTION</a></span> section for further information on viral reduction measures.)  Despite these measures, such products may still potentially contain human pathogenic agents, including those not yet known or identified. Thus the risk of transmission of infectious agents cannot be totally eliminated. Any <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to CSL Behring at 1-866-915-6958. The physician should discuss the risks and benefits of this product with the patient.</p>
<p>Albumin is a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) also is considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for albumin.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>GENERAL</h2>
<p class="First">If <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> is present additional fluids must accompany or follow the administration of albumin. Administration of large quantities of albumin should be supplemented with red blood cells or replaced by whole blood to combat the relative <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> which would follow such use. The quick response of blood pressure which may follow the rapid administration of concentrated albumin necessitates careful observation of the injured patient to detect <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> points which failed to bleed at lower blood pressure. Albumin (Human) 20% should be administered with caution to patients with low cardiac reserve or with no albumin deficiency because a rapid increase in plasma volume may cause circulatory embarrassment (e.g. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, or <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>). In cases of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, a slower rate of administration is desired - 200 mL of albumin solution may be mixed with 200 mL of 10% dextrose solution and administered at a rate of 10 grams of albumin (100 mL) per hour.</p>
<p>If anaphylactic or severe <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> occur, discontinue infusion immediately. Infusion rates and the patient's clinical state should be monitored closely during infusion.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>INFORMATION FOR PATIENT</h2>
<p class="First">Some viruses, such as parvovirus B19 or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> A are particularly difficult to remove or inactivate at this time. Parvovirus B19 may most seriously affect pregnant women, or immune-compromised individuals. The majority of parvovirus B19 and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> A <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> are acquired by environmental (community acquired) sources.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.3"></a><p></p>
<h2>PREGNANCY CATEGORY C</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.3.1"></a><p></p>
<p class="First">Animal reproduction studies have not been conducted with Albuminar<span class="Sup">®</span>-20. It is also not known whether Albuminar<span class="Sup">®</span>-20 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Albuminar<span class="Sup">®</span>-20 should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.4"></a><p></p>
<h2>PEDIATRIC USE</h2>
<p class="First">No clinical studies using Albuminar<span class="Sup">®</span>-20 have been conducted in pediatric patients. Safety and effectiveness in pediatric patients have not been established. However, extensive experience in patients suggests that children respond to Albuminar<span class="Sup">®</span>-20 in the same manner as adults.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The incidence of untoward reactions to Albuminar<span class="Sup">®</span>-20 is low. Reports have been received of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, which may be severe, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>). <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">increased salivation</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">febrile reactions</span> have also been reported (see also <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Albuminar<span class="Sup">®</span>-20 may be given intravenously without dilution or it may be diluted with normal saline or 5% dextrose before administration. 250 mL per liter gives a solution which is approximately isotonic and iso-osmotic with citrated plasma.</p>
<p>When undiluted albumin solution is administered in patients with normal blood volume, the rate of infusion should be slow enough to prevent too rapid expansion of plasma volume.</p>
<p>In the treatment of <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, an initial dose of 100 mL of the 20% albumin solution is given as rapidly as tolerated. If response within 30 minutes is inadequate, an additional 100 mL of 20% albumin solution may be given. Therapy should be guided by the clinical response, blood pressure and an assessment of relative <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. If more than 250 mL are given, or if <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> has occurred, the administration of packed red blood cells may be desirable.</p>
<p>In severe <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>, immediate therapy should include large volumes of crystalloid with lesser amounts of 20% albumin solution to maintain an adequate plasma volume and protein content. After the first 24 hours, the ratio of albumin to crystalloid may be increased to establish and maintain a plasma albumin level of about 2.5 g/100 mL or a total serum protein level of about 5.2 g/100 mL.</p>
<p>The infusion of Albumin (Human) as a nutrient in the treatment of chronic <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span> is not recommended. In acute <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span> 250-350 mL of 20% albumin may be required to reduce <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and to bring serum protein values to normal. Since such patients usually have approximately normal blood volume, the rate of administration should not be greater than 3 mL per minute to avoid circulatory embarrassment.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Albuminar<span class="Sup">®</span>-20 is supplied as a 20% solution. Each product presentation includes a package insert and the following component:</p>
<table width="75%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="left" valign="middle" width="60%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Presentation</th>
<th class="Rrule" align="center">Carton<br>NDC Number</th>
<th class="Rrule" align="left">Component</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">50 mL</td>
<td class="Rrule" align="center">0053-7695-33</td>
<td class="Rrule" align="left">One vial containing 10 grams of albumin<br>[NDC 0053-7695-90]</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">100 mL</td>
<td class="Rrule" align="center">0053-7695-34</td>
<td class="Rrule" align="left">One vial containing 20 grams of albumin<br>[NDC 0053-7695-91]</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-10.1"></a><p></p>
<p class="First">Store between 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F) [See USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-11"></a><p></p>
<h1>REFERENCES</h1>
<ol><li>Data on file.</li></ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1>BIBLIOGRAPHY</h1>
<p class="First">Finlayson, J.S.:  Albumin Products. <span class="Italics">Seminars in <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> and Hemostasis</span> 6:85-120, 1980.</p>
<p>Tullis, J.L.:  Albumin. <span class="Italics">JAMA</span> 237: 355-360 and 460-463, 1977.</p>
<p>Rudolph, A.M.:  <span class="Underline">Pediatrics</span>. 18th ED., p. 1839, Appleton and Lange, 1987.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<p class="First">Manufactured by:<br><span class="Bold">CSL Behring LLC</span><br>Kankakee, IL 60901 USA<br>US License No. 1767</p>
<p>Revised August, 2012<br>12480-06</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 50 mL Vial Label</h1>
<p class="First"><span class="Bold">NDC 0053-7695-90</span></p>
<p><span class="Bold">20%</span></p>
<p><span class="Bold">50 mL</span></p>
<p><span class="Bold"><span class="Bold">Albumin (Human)</span><br><span class="Bold">USP 20%</span><br>Albuminar<span class="Sup">®</span>-20</span></p>
<p>Store between 20-25°C (68-77°F); <br>excursions permitted to 15-30°C (59-86°F) <br>[See USP Controlled Room Temperature].</p>
<p><span class="Bold">Rx only<br> I.V. use only</span></p>
<p>Manufactured by:<br><span class="Bold">CSL Behring LLC</span><br>Kankakee, IL 60901 USA<br>US License No. 1767</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 50 mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a901aa63-3347-4a12-8c74-e7cdd6edbddc&amp;name=albuminar-20-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 50 mL Vial Carton</h1>
<p class="First"><span class="Bold">NDC 0053-7695-33</span></p>
<p><span class="Bold">20%</span></p>
<p><span class="Bold">50 mL</span></p>
<p><span class="Bold"><span class="Bold">Albumin (Human)</span><br><span class="Bold">USP 20%</span><br>Albuminar<span class="Sup">®</span>-20</span></p>
<p><span class="Bold">For Intravenous Administration Only.</span></p>
<p>10 g in 50 mL solution osmotically equivalent to <br>200 mL of plasma.</p>
<p>Do not use if turbid.</p>
<p>Do not begin administration more than 4 hours <br>after the container has been entered.</p>
<p>Store between 20-25°C (68-77°F); excursions <br>permitted to 15-30°C (59-86°F) [See USP <br>Controlled Room Temperature].</p>
<p><span class="Bold">Rx only</span></p>
<p>Manufactured by:<br><span class="Bold">CSL Behring LLC</span><br>Kankakee, IL 60901 USA<br>US License No. 1767</p>
<p><span class="Bold">CSL Behring</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 50 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a901aa63-3347-4a12-8c74-e7cdd6edbddc&amp;name=albuminar-20-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALBUMINAR-20 		
					</strong><br><span class="contentTableReg">albumin (human) solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0053-7695</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Albumin Human</strong> (Albumin Human) </td>
<td class="formItem">Albumin Human</td>
<td class="formItem">20 g  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span></strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Acetic Acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0053-7695-33</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0053-7695-90</td>
<td class="formItem">50 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0053-7695-34</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0053-7695-91</td>
<td class="formItem">100 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103955</td>
<td class="formItem">01/06/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>CSL Behring LLC
							(058268293)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">CSL Behring LLC</td>
<td class="formItem"></td>
<td class="formItem">058268293</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>37faea5f-f558-4102-a9db-93b1510a22b7</div>
<div>Set id: a901aa63-3347-4a12-8c74-e7cdd6edbddc</div>
<div>Version: 5</div>
<div>Effective Time: 20130805</div>
</div>
</div> <div class="DistributorName">CSL Behring LLC</div></p>
</body></html>
